Please try another search
For the six months ended 30 June 2012, Viaderma Increvenues decreased 11% to $9.6M. Net income decreased 21%to $1.4M. Revenues reflect a decrease in demand for theCompany's products and services due to unfavorable marketconditions. Net income also reflects Interest expenseincrease of 87% to $371K (expense). Basic Earnings perShare excluding Extraordinary Items decreased from $12.50to $9.88.
Period Ending: | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 |
---|---|---|---|---|
Total Revenue | 5.82 | 3.82 | 3.79 | 4.38 |
Gross Profit | 1.94 | 1.08 | 0.87 | 1.25 |
Operating Income | 1.52 | 0.73 | 0.81 | 0.68 |
Net Income | 0.95 | 0.4 | 0.53 | 0.42 |
Period Ending: | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 |
---|---|---|---|---|
Total Assets | 45.83 | 44.93 | 42.65 | 42.98 |
Total Liabilities | 10.73 | 10.81 | 9.09 | 10.28 |
Total Equity | 35.1 | 34.12 | 33.56 | 32.7 |
Period Ending: | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | 4.04 | 2 | 6.05 | 3.67 |
Cash From Investing Activities | -2.53 | -0.54 | -9.43 | -8.15 |
Cash From Financing Activities | -0.89 | -0.67 | 2.95 | 3.78 |
Net Change in Cash | 0.61 | 0.79 | -0.39 | -0.67 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review